Acknowledgements
Nürnberg, Thomas Kindler
REITER
We thank Kim Kricheldorf for support with the GSG-MPN bioregistry coordination, Carmen Fera, Michelle Haaße, Yvonne Schumacher, Amrei Pelzer, Christina Grohe, Irina Prell, Verena Deserno, and Rainer Schuckelt for support at the Center for Translational and Clinical Research Aachen (CTC-A), Kristina Pannen (née Feldberg) for logistic support with samples, and Britta Wagner for excellent secretarial assistance. We thank our colleagues and study staff at all RuxoBEAT study centers in Germany and our patients for participation in this trial. Additional centers participating in this study include Aschaffenburg (Martine Klausmann), Berlin (Philip LeCoutre), Chemnitz (Mathias Hänel), Düsseldorf University Hospital (Norbert Gattermann), Essen (Joachim R. Göthert), Mainz (Thomas Kindler), Mannheim (Andreas Reiter), Münster (Eva Eßeling), Nürnberg (Marinela Augustin), Duisburg (Sebastian Balleisen), Halle (Haifa Kathrin Al-Ali), Düsseldorf Marien-Hospital (Aristoteles Giagounidis), Siegburg (Stefan Fronhoffs), and Cologne (Christof Scheid). We thank Novartis for the financial support of the clinical trial and for providing the study medication. We thank the Deutsche Forschungsgemeinschaft (DFG) for supporting concomitant basic research associated with this entire trial within the Clinical Research Unit CRU344 (KO 2155/7-1, BR 1782/5-1).